
Feature|Videos|December 2, 2024
Combined platform and modalities marriages.
Looking ahead 5-10 years for in vivo practice. Combined platform and modalities marriages, to bring CGT up to first relapse or consolidation therapies.
Advertisement
Episodes in this series
In this exclusive BioPharm International Peer Exchange video series, Chris Spivey, Director of Industry Relations and Strategic Partnerships, talks with industry experts about various aspects of Cell and Gene Therapies with a focus on reducing manufacturing bottlenecks by creating smaller automated footprint installations, better integrating analytics advances including harnessing artificial intelligence, and above all lowering barriers to access by lowering costs while improving timelines.
Advertisement
Related to this article

mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.

Verismo will pair Stanford's PACK-IT lentiviral technology with its KIR-CAR platform to pursue off-the-shelf, in vivo CAR T therapies for cancer.

Visara has dosed the first patient in ASCEND, a roughly 244-patient, head-to-head phase 2b trial comparing two doses of its tetravalent VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in treatment-naïve wet AMD. The study will test dosing intervals of up to seven months and select the dose for a global phase 3 program planned as early as 2027.

The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.

FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.

Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.

Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.

Commit Biologics Raises $60 Million to Take Complement-Powered Immune Engager COM002 Into the Clinic
Danish biotech Commit Biologics closed a $60 million seed round led by Ackermans & van Haaren, with AbbVie Ventures and M Ventures joining, to advance COM002, a bispecific antibody that recruits complement rather than T cells to eliminate diseased cells.
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Approves Cosentyx as First Anti-IL-17 Biologic for Polymyalgia Rheumatica
2
One Injection a Month: Efimosfermin Takes Aim at Cirrhosis in MASH
3
The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
4
Deals Roundup: J&J Buys Ollin, Lilly Adds Calytrix, and Novartis and Sanofi Strike Platform Pacts
5

